Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Other financing activities (2016 - 2022)

Bristol Myers Squibb (BMYMP) has disclosed Other financing activities for 14 consecutive years, with $179.0 million as the latest value for Q4 2022.

  • Quarterly Other financing activities rose 6066.67% to $179.0 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $984.0 million through Dec 2022, up 53.51% year-over-year, with the annual reading at $27.0 million for FY2023, 97.26% down from the prior year.
  • Other financing activities for Q4 2022 was $179.0 million at Bristol Myers Squibb, up from $53.0 million in the prior quarter.
  • The five-year high for Other financing activities was $419.0 million in Q2 2022, with the low at -$58.0 million in Q1 2018.
  • Average Other financing activities over 5 years is $103.0 million, with a median of $35.5 million recorded in 2020.
  • The sharpest move saw Other financing activities tumbled 1400.0% in 2019, then surged 17200.0% in 2020.
  • Over 5 years, Other financing activities stood at $1.0 million in 2018, then crashed by 1400.0% to -$13.0 million in 2019, then skyrocketed by 2230.77% to $277.0 million in 2020, then tumbled by 101.08% to -$3.0 million in 2021, then surged by 6066.67% to $179.0 million in 2022.
  • According to Business Quant data, Other financing activities over the past three periods came in at $179.0 million, $53.0 million, and $419.0 million for Q4 2022, Q3 2022, and Q2 2022 respectively.